CVR: 41244909
HyperBio Therapeutics ApS was a Danish company of the type Anpartsselskab based in Vejle Øst, founded in 2020 and dissolved in 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2023, the company reported a gross profit of DKK -74,484 and a net result of DKK -972,747 compared with DKK -7,656,366 the year before. Equity amounted to DKK 739,784.
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringScreen owners and management against the Danish FSA's official PEP lists
As of January 14, 2025, Søren Sylvester Skjærbæk has stepped down as liquidator of HyperBio Therapeutics ApS.
On January 14, 2025, HyperBio Therapeutics ApS exited liquidation.
HyperBio Therapeutics ApS was dissolved on January 14, 2025.
As of July 2, 2024, Søren Sylvester Skjærbæk is registered as liquidator of HyperBio Therapeutics ApS.
As of July 2, 2024, Søren Sylvester Skjærbæk has stepped down as director of HyperBio Therapeutics ApS.
As of July 2, 2024, Morten Døssing has stepped down as chairman of HyperBio Therapeutics ApS.
On July 2, 2024, HyperBio Therapeutics ApS entered liquidation.
HyperBio Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -74,484, and the net result was DKK -972,747.
HyperBio Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -8,628,935, and the net result was DKK -7,656,366.
As of June 9, 2023, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has stepped down as auditor of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -12,881,904, and the net result was DKK -10,612,873.
As of June 18, 2021, Niccolo' Bacchi-Bønnelykke has left the board of directors of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS has published its interim report for the period March 12, 2020 – December 31, 2020.
As of March 12, 2020, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of HyperBio Therapeutics ApS.
As of March 12, 2020, Niccolo' Bacchi-Bønnelykke has joined the board of directors of HyperBio Therapeutics ApS.
As of March 12, 2020, Søren Sylvester Skjærbæk is registered as director of HyperBio Therapeutics ApS.
As of March 12, 2020, Morten Døssing is registered as chairman of HyperBio Therapeutics ApS.
HyperBio Therapeutics ApS was founded on March 12, 2020.
Companies in the same industry and area
CVR 30738276
CVR 25577922
CVR 29428514
CVR 42036099
CVR 44395665
companydata.dk